FendX Technologies Inc. (CSE: FNDX): Developing Products to Reduce the Spread of Pathogens

This is a paid advertisement on behalf of FendX Technologies Inc. 

Nanotechnology: An Investment in the Future of Controlling the Spread of Pathogens

In the not-so-distant past, during the height of the pandemic, we found ourselves hyper-aware of every surface we touched, the potential diseases they harbored, and the risk of transmission. 

Today, innovative nanotechnology exists that promises to reduce the spread of pathogens across numerous industries and settings – a new technology that investors can access via the public markets, at an early stage before initial scale-up manufacturing puts this technology on the path to commercialization.

Taking a Leaf out of Nature’s Book: The Lotus Leaf Inspiration

The genesis of this technology lies in the natural world, more specifically, the water-resistant properties of the lotus leaf. This extraordinary plant has long captivated both onlookers with its beauty and scientists with its effortless ability to repel water, dirt, and other contaminants. 

This remarkable trait stems from the microscopic structure of its surface, which prevents adherence of water droplets and contaminants. Drawing from the lotus leaf’s resilience, researchers at McMaster University have crafted a nanotechnology that replicates this natural phenomenon, creating surfaces that are instantaneously inhospitable to pathogens.

Introducing FendX Technologies Inc.: A Potentially High-Growth Opportunity in Antiviral and Antimicrobial Nanotechnology

FendX Technologies (CSE: FNDX) was born of a small collection of experienced medical industry professionals who recognized the potential of this innovative nanotechnology and seized the opportunity to license it from McMaster University. 

FendX’s technology has unique repelling properties that prevent the adhesion of bacteria, viruses, and liquids, thereby reducing their transmission on surfaces prone to contamination.

Their lead product under development, REPELWRAP™ film, is a protective surface coating film with these unique repelling properties. They are also exploring additional applications using their nanotechnology, such as enhancements to REPELWRAP™ film and coating of catheters to prevent occlusion from bacterial biofilm formation and blood clots.

Why Consider Early Investment in FendX Technologies?

1.  Market Disruption: FendX is looking to redefine the antimicrobial and antiviral market with a novel product. REPELWRAP™ film which has demonstrated unique repelling properties that prevent the adhesion of pathogens, bacteria, and viruses, reducing their transmission on surfaces prone to contamination.

2.  Attractive Valuation: FendX’s innovative technology does provide a potentially compelling investment opportunity compared to other companies in the sector.

3.  Expanding Product Range: While REPELWRAP™ film in development is the first go-to-market product, FendX’s technology has potential for expansion into various other applications. Investing now allows one to capitalize on the company’s future potential growth as it explores other applications and products.

4.  Inflection Point: FendX has recently signed a development stage agreement with Dunmore International Corp., a global manufacturer of engineered coated and laminated films, to conduct the initial scale up of REPELWRAP™ film.  Once intermediate sized samples are successfully tested, REPELWRAP™ film will then scale up to commercial production.
   This is an important milestone, indicating that the company is moving from the research phase to the production phase.

5.  Diverse Market Potential: Healthcare is the initial target market because of its immediate and obvious lifesaving applications.
   Note: The annual economic burden of healthcare-associated infections (HAIs) in Europe is estimated to be approximately 7 billion EUR (Future Markets Technology Report, 2023), and in the US, direct medical costs associated with HAIs are no less than $28.4 billion USD each year, coupled with societal costs of $12.4 billion USD from premature deaths and lost productivity (CDC, 2023)¹.
   1. Centers for Disease Control and Prevention. (2023). Healthcare-associated infections (HAI). Retrieved from https://www.cdc.gov/policy/polaris/healthtopics/hai/index.html
   However, FendX’s technology has the potential to be adopted by many other industries, offering a broad market opportunity. Early investment allows one to share in the upside of the company’s growth as it captures market share across sectors.
   
   
6. Experienced Management Team: FendX is led by a seasoned team of professionals with extensive experience in the medical and technology industries. This expertise provides a solid foundation for the company’s initial market penetration and further growth. 
   
7.  Strong Intellectual Property: FendX’s technology is building a robust intellectual patent-pending property portfolio, including patents and trade secrets, which will help protect the company’s innovations and provide a competitive edge in the market.
   
   
8.  Positive Industry Outlook: The demand for effective antimicrobial and antiviral products is only expected to grow, fueled by increasing concerns over public health and hygiene. FendX’s innovative technology is well-positioned to potentially capitalize on this growing demand.

A Compelling Investment Opportunity: Favorable Share Structure and Rapid Upside Potential

One additional standout aspect that makes FendX Technologies an appealing investment proposition is its ‘tight’ share structure. 

As of May 11, 2023, the company has total outstanding common shares of 51,946,786 with 35,649,666 of those shares subject to voluntary pooling and escrow restrictions. This results in an extremely small float of just over 16,000,000 shares. 

This supply-demand dynamic can potentially lead to fast price appreciation, offering an attractive opportunity for investors who understand and are comfortable with this kind of speculative investment.

Any positive news flow from FendX Technologies presents an opportunity for a swift rerating and potential market cap growth.

Investors looking for exposure to a potentially high-growth, innovative company in the nanotechnology market are invited to take a closer look at FendX Technologies Inc.. With its tight share structure, pioneering nanotechnology, and a seasoned team of industry professionals with extensive experience in bringing products to market in the healthcare industry, FendX is well-positioned to first penetrate the healthcare market and grow beyond it.

To delve deeper into FendX Technologies and the investment opportunity it presents, kickstart your due diligence process and explore the company’s fact sheet and website linked below.

Bill McClain – Editor of The Momentum Letter
About the author.

FendX Company Website: https://fendxtech.com/

FendX Technologies Inc. General Disclaimer
This article contains certain forward-looking statements within the meaning of Canadian securities
legislation (the “Forward-looking Statements”), including with respect to: the plans of FNDX;
expectations regarding industry trends, including with respect to the antimicrobial surface market,
overall market growth rates and FNDX’s growth rates and growth strategies; that microbe repellent
technology is a promising, high-growth industry; the use of available funds; the performance of FNDX’s
business and operations; FNDX’s expectations regarding revenues, expenses and anticipated cash needs;
the intention to grow FNDX’s business and operations; the expected timing and completion of FNDX’s
nearterm objectives; laws and regulations and any amendments thereto applicable to FNDX; FNDX’s
competitive advantages and business strategies; FNDX’s future product offerings; FNDX’s research and
development initiatives and expected results thereof; FNDX’s growing patent portfolio; FNDX’s ability to
enter into distribution, manufacturing and other business relationships; the potential of FNDX’s
technology to protect against the spread of pathogens on surfaces through repelling bacteria and
viruses that come in contact with its surface; that FNDX’s technology will bring significant value in
controlling the spread of surface borne infectious diseases; that FNDX’s technology could be a key
weapon to contribute in the battle against the growing global threat of infectious disease transmission;
that FNDX’s technology could be deployed all over the world and it could save human lives; that spread
of infectious disease is a deadly problem which is getting worse; that for businesses and governments
looking to mitigate the spread of pathogens, FNDX’s nanotechnology could be part of the answer; if
commercialized, FNDX’s technology could address the urgent need for innovative solutions to help
control the spread of pathogens on surfaces – especially in healthcare; FNDX’s proprietary REPELWRAP™
film could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help
prevent pathogen transmission; FNDX’s nanotechnology has the potential to be applied to other types
of surfaces and materials – such as catheters which could significantly help reduce blockages caused by
bacterial colony and/or blood clot formation in long-use catheters and that underserved markets like
this offer potentially future upside, if FNDX can successfully adapt their technology; FNDX’s intention to
initially target REPELWRAP TM film towards healthcare settings and high traffic public touchpoints; that as
FNDX continues its product development, we may see it used to protect surfaces in other high traffic
places like the transportation, sports and entertainment, hospitality, and education sectors; the growing
global commitment to reduce the spread of pathogens; and that REPELWRAP™ film will provide
additional protection to current disinfecting practices to control the spread of pathogens. Although
FNDX believes that such statements are reasonable, it can give no assurance that such expectations will
prove to be correct. Forward-looking statements are statements that are not historical facts; they are
generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,”
“intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar
expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are
those statements, which, by their nature, refer to future events. FNDX cautions that forward-looking
statements are based on the beliefs, estimates and opinions of FNDX’s management on the date the
statements are made and they involve a number of risks and uncertainties. Consequently, there can be
no assurances that such statements will prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause future results to differ materially from those anticipated in these
forward-looking statements include: product candidates only being in formulation/reformulation stages;

limited operating history, no revenues and uncertainty around additional financing; negative cash flow
history; no production history and lack of revenues from sales; no history of manufacturing or
distribution; highly competitive industry; satisfying the terms of the License Agreement and
Collaborative Research Agreement between FNDX and McMaster University and maintaining the License
in good standing; inability of McMaster University to satisfy the terms under the License Agreement and
Collaborative Research Agreement; completion of scale-up and development of a commercial product;
research and development activities; reliance on grant funding; limited number of products;
dependence on collaborative partners, licensors and others; changes and restrictions due to legal and
regulatory requirements; dependence on each product’s acceptance in the market; possibility of smaller
market opportunities than anticipated; increasing regulatory and compliance costs for public companies;
global economic instability; product liability claims and lawsuits; system failures; reliance on
management and loss of key employees or inability to hire key personnel; limited experience of senior
management in managing a public company; fraudulent or illegal activity by employees, contractors and
consultants; inability to effect service of process on some of FNDX’s directors and officers;
management’s efforts and abilities; potential conflicts of interest; inability to protect intellectual
property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary
rights of third parties; risks related to forward-looking information; volatility of the market price of
FNDX’s common shares; potential dilution of the common shares; lack of an active, liquid and orderly
trading market for the common shares; failure of securities or industry analysts to publish research or
publish inaccurate or unfavourable research about FNDX; inability or unwillingness to pay dividends;
exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public
health crisis or another global health pandemic; use of available funds; effect of general economic and
political conditions; internal controls; and other risk factors set forth in FNDX’s final prospectus dated
January 31, 2023 under the heading “Risk Factors” and other filings, publicly available through the
Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) at
www.sedar.com. The reader is urged to refer to FNDX’s prospectus and other filings, publicly available
through SEDAR at www.sedar.com for a more complete discussion of such risk factors and their
potential effects. Except to the extent required by applicable securities laws and the policies of the
Canadian Securities Exchange, FNDX undertakes no obligation to update these forward-looking
statements if management’s beliefs, estimates or opinions, or other factors, should change. New factors
emerge from time to time, and it is not possible for FNDX to predict all of them or assess the impact of
each such factor or the extent to which any factor, or combination of factors, may cause results to differ
materially from those contained in any Forward-looking Statement. Any Forward-looking Statements
contained in this article are expressly qualified in their entirety by this cautionary statement.
While the information contained in this article is believed to be accurate, FNDX expressly disclaims any
and all liability for any losses, claims or damages of whatsoever kind based upon the information
contained in, or omissions from, this article or any oral communication transmitted in connection
therewith. In addition, none of the statements contained in this article are intended to be, nor shall be
deemed to be, representations or warranties of FNDX. Where the information is from third-party
sources, the information is from sources believed to be reliable, but FNDX has not independently
verified any of such information contained herein.
This article is not, and under no circumstances is to be construed as, a prospectus, an offering
memorandum, an advertisement or a public offering of securities. Under no circumstances should the

information contained herein be considered an offer to sell or a solicitation of an offer to buy any
securities.

GENERAL DISCLAIMER
Triple Bull Consulting Inc. (“Triple Bull”) and its affiliates or partners will seek to provide
services to companies mentioned on the TheMomentumLeter.com website. Hence, all
information available on TheMomentumLeter.com should be considered as commercial
advertisement and not an endorsement, offer or recommendation to buy or sell
securities. Triple Bull and its related companies (including its directors, employees and
representatives) or a connected person may have ownership/stock positions in, or
options on the securities detailed in this report, and may buy, sell or offer to purchase or
sell such securities from time to time.

Triple Bull and/or its affiliates and/or their respective officers, directors or employees
may from time to time acquire, hold or sell securities and/or commodities and/or
commodity futures contracts in certain underlying companies mentioned in this site and
which may also be clients of Triple Bull’s affiliates. In such instances, Triple Bull and/or
its affiliates and/or their respective officers, directors or employees will use all
reasonable efforts to avoid engaging in activities that would lead to conflicts of interest
and Triple Bull and/or its affiliates will use all reasonable efforts to comply with
conflicts of interest disclosures and regulations to minimize the conflict.

Specifically all companies mentioned or listed as “Sponsored” at
TheMomentumLeter.com. and which are shown under the heading “Sponsored” on the
site have entered into a commercial relationship with Triple Bull or our affiliates for
capital market services and have paid fees and/or shares or stock options or warrants
for being featured and mentioned in TheMomentumLeter.com. Hence these
“Sponsored” at TheMomentumLeter.com are shown at the website as an advertisement
only and any mention of these companies does not and will not constitute an offer to
buy or sell securities in the featured companies. Triple Bull, its affiliates or partners will
seek to provide services to companies mentioned in TheMomentumLeter.com website.
Hence, all information available on TheMomentumLeter.com should be considered as
commercial advertisement and not an endorsement, offer or recommendation to buy or
sell securities.

Triple Bull is not registered with any financial or securities regulatory authority in British
Columbia or Canada, and does not provide nor claims to provide investment advice or
recommendations to any visitor of this site or readers of any content on this site.

The information on this site is for informational purposes only. This site, including the
data, information, research reports, press releases, findings, comments, views and
opinions of Triple Bull’s analysts, columnists, speakers or commentators, and other
contents contained in it, is not intended to be: investment, tax, banking, accounting,
legal, financial or other professional or expert advice of Triple Bull or its affiliates, or a
recommendation, solicitation or offer by Triple Bull or its affiliates to buy or sell any
securities, futures, options or other financial instruments, and such information should
not be relied upon for such advice. Every user of this site is advised to seek professional
advice before acting or omitting to act on any information contained in the site.

Research reports and newsletters have been prepared without reference to any
particular user’s investment requirements or financial situation. Where reference is

made to estimate of value or relative value of a specific company, there is no guarantee
that these estimates are reliable or will materialize. Readers of these reports and
newsletters are advised to conduct their own due diligence before making any
investment decisions. Triple Bull does not make independent investigation or inquiry as
to the accuracy and completeness of any information provided by the “Sponsored”
companies. Although the content has been obtained from sources believed to be
reliable, this website could include technical or other inaccuracies or typographical
errors and it is provided to you on an “as is” basis without warranties or representations
of any kind. Triple Bull and its affiliates make no representation and disclaim all express
and implied warranties and conditions of any kind, including without limitation,
representations, warranties or conditions regarding accuracy, timeliness, completeness,
non-infringement, satisfactory quality, merchantability, merchantable quality or fitness
for any particular purpose or those arising by law, statute, usage of trade, or course of
dealing. Triple Bull and its affiliates assume no responsibility to you or any third party
for the consequences of any errors or omissions.

Information in this site is subject to change without notice. Triple Bull assumes no
liability for any inaccurate, delayed or incomplete information, nor for any actions taken
in reliance thereon.

Triple Bull, its affiliates and their respective directors, officers, employees, or agents
expressly disclaim any liability for losses or damages, whether direct, indirect, special,
or consequential, or other consequences, howsoever caused, arising out of any use or
reproduction of this site or any decision made or action taken in reliance upon the
content of this site, whether authorized or not. By accessing this site, each user of this
site releases Triple Bull, its affiliates and their respective officers, directors, agents and
employees from all claims and proceedings for such losses, damages or
consequences.

Triple Bull and its affiliates do not endorse or recommend any securities issued by any
companies identified on, or linked through, this site. Please seek professional advice to
evaluate specific securities or other content on this site. Links, if any, to third party sites
are for informational purposes only and not for trading purposes. Triple Bull and its
affiliates have not prepared, reviewed or updated any content on third party sites and
assume no responsibility for the information posted on them.

Triple Bull and/or its affiliates and/or their respective officers, directors or employees
may from time to time acquire, hold or sell securities and/or commodities and/or
commodity futures contracts mentioned in this site.

This site may include forward-looking statements about objectives, strategies and
expected financial results of companies featured in this site or where research reports
are available on companies displayed and/or featured on this site. Such forward-looking
statements are inherently subject to uncertainties beyond the control of such
companies. The users of this site are cautioned that the company’s actual performance
could differ materially from such forward-looking statements.

World Wide Web sites accessed by hypertext links (“hyperlinks”) appearing in this site
have been independently developed by parties other than Triple Bull and Triple Bull has
no control over information in any hyperlinked site. Triple Bull is providing hyperlinks to
users of this site only as a convenience. Triple Bull makes no representation and is not
responsible for the quality, content or reliability of any information in any hyperlinked
site. The inclusion of any hyperlink in this site should not be construed as an
endorsement by Triple Bull of the information in such hyperlinked site and does not
imply that Triple Bull has investigated, verified or monitored the information in any such
hyperlinked site. Should you wish to inquire about creating a link from your World Wide
Web site to this site, contact marketing via e-mail at:
marketing@triplebullconsulting.com for written authorization.

Any non-personal communication, comments, ideas or material you post or transmit to
Triple Bull through its website is, and will be treated as, non-confidential and non-
proprietary. By transmitting or posting any communication or material to this web site
you grant to Triple Bull and all of its affiliates, an unrestricted, irrevocable license to use,
reproduce, display, modify, transmit, distribute, publish, broadcast or post your
communication for any purpose. You also agree that Triple Bull is free to use any ideas,
concepts, know-how or techniques that you send us for any purpose through this
website. However, we will not release your name or otherwise publicize the fact that you
submitted materials or other information to us through this website unless:

• you grant us permission to do so;
• we first notify you that the materials or other information you submit to a particular
  part of a site will be published or otherwise used with your name on it; or
• we are required to do so by law.